Close
Close

13th International Conference on Myasthenia Gravis and Related Disorders in New York (US)

3.33333333333
3.3 from 6 votes
Date: 15 - 17 May, 2017
Location: New York, United States

The treatment for (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness and fatigue, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. While modern medical advances have reduced MG mortality rates over the last several decades, there has been an increase in reported cases especially among the aging population. The number of diagnosed MG cases is expected to rise as the aging population increases and screening techniques for MG improve. From a public health perspective it is clear that increased understanding of the etiology underlying MG is critical for enhancing diagnosis and treatment of this disease. To better translate basic research discoveries into the standard treatment regimen of MG patients, the New York Academy of Sciences, in partnership with the Myasthenia Gravis Foundation of America, will organize the 13th International Conference on Myasthenia Gravis and Related Disorders.

The conference will provide a forum for basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis. The goals of this program are to: 1) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; 2) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; 3) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; and 4) identify knowledge gaps and future directions of research required for further breakthroughs. Ten plenary sessions will span the full spectrum of research from bench to bedside, including structure and function of the neuromuscular junction, advances in immunology, recent clinical developments related to MG, outcome measurements, clinical trial development, animal models of neuromuscular disease, MG treatment updates, congenital and Lambert-Eaton myasthenic syndromes, thymectomy, and the MGTX trial.

REGISTER

3.33333333333
3.3 from 6 votes